This article was originally published in The Rose Sheet
Executive SummarySecond-quarter sales for Procter & Gamble's Beauty unitwith "Smart Guy" brush initiative while Crest enjoyed "mid-single-digit" growth on strength of Pro-Health Night and Crest Plus Scope launches; overall Health Care sales advanced 11% to $3.8 bil. Firm's total net sales for Q2 were $21.6 bil., up 9%, with double-digit growth in developing regions, P&G says. Effective this month, P&G is increasing its price for Safeguard and Zest bar soaps by 8% due to an increase in commodity and energy costs...
You may also be interested in...
W3ll People is expected to add a relatively modest $7m to e.l.f. Beauty’s fiscal 2021 top line, but the brand has “major white space” opportunities, including at Target, e.l.f.’s longest-standing customer. Further, its plant-based product line includes 40 “EWG Verified” products, reflecting expertise e.l.f. is eager to tap.
UCB's R&D efforts include late-stage diverse but complementary immunologicals and anti-neuroinflammatories.
Janssen and AstraZeneca are among a raft of companies that might this week find out whether the European Medicines Agency will recommend approval of their products for expanded therapeutic indications.